Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Empli-03
- Development stage
- Phase 1
- Lead developer
- Emplicure
- Modality
- Small Molecules
- Administration
- Buccal
01
Overview
Empli-03 is an investigational oral buccal tablet containing buprenorphine, developed by Emplicure AB for the treatment of moderate to severe chronic pain. Utilizing the proprietary Emplior bioceramic technology platform, the formulation is designed to provide extended and controlled release of the active ingredient when placed under the upper lip. This bioceramic delivery system also incorporates abuse-deterrent features intended to limit manipulation and misuse. Buprenorphine acts as a partial agonist at the mu-type opioid receptor and an antagonist at the kappa-type opioid receptor. Empli-03 has completed a Phase I pharmacokinetic study demonstrating a steady release profile in healthy volunteers.
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Empli-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Empli-03.